Login / Signup

Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.

Lei ChengGuanghui GaoChao ZhaoHaowei WangChao YaoHanchuanzhi YuJichen YaoFeng LiLijie GuoQijie JianXiaoxia ChenXuefei LiCaicun Zhou
Published in: Cancer medicine (2023)
The tumor-informed assay was favorable for ctDNA detection, and early dynamic changes in plasma ctDNA may be a valuable biomarker for monitoring the efficacy and predicting the outcome in advanced NSCLC patients treated with first-line ICIs ± chemotherapy.
Keyphrases